Application of adaptive design and decision making to a phase II trial of a phosphodiesterase inhibitor for the treatment of intermittent claudication-Reference-Cited by-同舟云学术

Application of adaptive design and decision making to a phase II trial of a phosphodiesterase inhibitor for the treatment of intermittent claudication

Published:2011-05-25 Issue:1 Volume:12 Page:
ISSN:1745-6215
Container-title:Trials
language:en
Short-container-title:Trials

Author:

Lewis Roger J,Connor Jason T,Teerlink John R,Murphy James R,Cooper Leslie T,Hiatt William R,Brass Eric P

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Medicine (miscellaneous)

Link

http://link.springer.com/article/10.1186/1745-6215-12-134/fulltext.html

Reference9 articles.

1. Welten GM, Schouten O, Hoeks SE: Long-term prognosis of patients with peripheral arterial disease: a comparison in patients with coronary artery disease. J Am Coll Cardiol. 2008, 51: 1588-96. 10.1016/j.jacc.2007.11.077.

2. Steg PG, Bhatt DL, Wilson PW: One-year cardiovascular event rates in outpatients with atherothrombosis. JAMA. 2007, 297: 1197-206. 10.1001/jama.297.11.1197.

3. Hirsch AT, Criqui MH, Treat-Jacobson D: Peripheral arterial disease detection, awareness, and treatment in primary care. JAMA. 2001, 286: 1317-24. 10.1001/jama.286.11.1317.

4. Hirsch AT, Haskal ZJ, Hertzer NR: ACC/AHA 2005 guidelines for the management of patients with peripheral arterial disease (lower extremity, renal, mesenteric, and abdominal aortic): executive summary a collaborative report from the American Association for Vascular Surgery/Society for Vascular Surgery, Society for Cardiovascular Angiography and Interventions, Society for Vascular Medicine and Biology, Society of Interventional Radiology, and the ACC/AHA Task Force on Practice Guidelines (Writing Committee to Develop Guidelines for the Management of Patients With Peripheral Arterial Disease) endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation; National Heart, Lung, and Blood Institute; Society for Vascular Nursing; TransAtlantic Inter-Society Consensus; and Vascular Disease Foundation. J Am Coll Cardiol. 2006, 47: 1239-312. 10.1016/j.jacc.2005.10.009.

5. Pande RL, Hiatt WR, Zhang P, Hittel N, Creager MA, McDermott M: A pooled analysis of the durability and predictors of treatment response of cilostazol in patients with intermittent claudication. Vasc Med. 2010, 15: 181-8. 10.1177/1358863X10361545.

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Beyond the heart - Exploring the therapeutic potential of PDE3 inhibitors;Journal of Research in Pharmacy;2023

2. Cilostazol for intermittent claudication;Cochrane Database of Systematic Reviews;2021-06-30

3. Opportunity for efficiency in clinical development: An overview of adaptive clinical trial designs and innovative machine learning tools, with examples from the cardiovascular field;Contemporary Clinical Trials;2021-06

4. Cilostazol for intermittent claudication;Cochrane Database of Systematic Reviews;2014-10-31

5. Clinical and Molecular Genetics of the Phosphodiesterases (PDEs);Endocrine Reviews;2013-12-05